radium ra-223 dichloride
bayer
['reassure', 'crpc']
poster 225, presented by nicholas james at #asco22, examines alkaline phosphatase (alp) decline &amp; os in patients with mcrpc treated with 223ra (reassure study), finding that alp decline at 12 weeks 223ra treatment had longer os than with no alp decline. #meded 
Independent and international experts in GenitoUrinary (GU) oncology. Part of https://t.co/QAbKORwRcf